Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC),...
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the...
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1...
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results 1 Group performance 2...
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4...
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate...
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader...
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT...
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European...
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New...